DARE
Daré Bioscience, Inc.
There isn't enough reported data to score DARE yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
DARE Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
DARE's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
DARE PE Valuation
DARE has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
DARE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect DARE's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
DARE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.80 | +$1.35 |
| Q1 2026 | -$1.05 | -$0.87 |
| Q4 2025 | -$1.34 | -$0.82 |
| Q3 2025 | -$1.88 | -$1.17 |
| Q2 2025 | -$2.15 | -$0.91 |
| Q1 2025 | -$0.18 | +$3.78 |
| Q4 2024 | -$0.52 | +$3.68 |
| Q3 2024 | -$0.71 | +$4.93 |
DARE is still losing money, but far less than before: $0.80 per share over the past year, against $11.64 at its worst in late 2019.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over DARE on earnings quality, reporting a profit while its opponent remains loss making.
DARE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $152.5K | +500% |
| Q3 2025 | $2.3K | -95% |
| Q1 2025 | $25.4K | +173% |
| Q3 2024 | $41.7K | -96% |
DARE's revenue has slid since its 2022 peak: $187,546 last quarter, down 986% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1583% | N/A |
| Q1 2026 | -1967% | +16050 points |
| Q4 2025 | -144% | N/A |
| Q3 2025 | -162341% | -151112 points |
| Q1 2025 | -18017% | +46727 points |
| Q3 2024 | -11229% | -10389 points |
| Q2 2024 | -32799% | N/A |
| Q1 2024 | -64744% | N/A |
DARE's operating margin was −1583% last quarter, up 16434 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over DARE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over DARE on profitability, with a higher operating margin.
DARE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.9M | -$1.6M |
| Q1 2026 | -$5.5M | +$107.2K |
| Q4 2025 | $1.2M | -73% |
| Q3 2025 | -$616.8K | +$5M |
| Q2 2025 | -$5.3M | -142% |
| Q1 2025 | -$5.6M | +$1.2M |
| Q4 2024 | $4.7M | +$13.4M |
| Q3 2024 | -$5.6M | +$2.4M |
DARE has burned cash in most quarters: −$12M over the past year, against −$12M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over DARE on cash generation, producing positive trailing cash flow while its opponent burns cash.
DARE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.5% | +367K shares |
| 1 year | +70% | +6.1M shares |
| 3 years | +109% | +7.8M shares |
| 5 years | +466% | +12.3M shares |
DARE has 15M diluted shares, up 70% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q4 2024 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over DARE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
DARE Net Leverage
DARE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
DARE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.2 | Neutral |
| Stochastic | 4.6 | Oversold |
DARE's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
DARE PE vs Healthcare Sector
DARE has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
DARE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.72 | 11% below |
| 20 week MA | $1.02 | 37% below |
| 50 week MA | $1.60 | 60% below |
| 100 week MA | $2.11 | 70% below |
| 200 week MA | $4.43 | 86% below |
DARE is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over DARE on trend strength, trading above more of its moving averages.
DARE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.84 | $16.9 | +72% |
| 2021 | $16.9 | $24.8 | +47% |
| 2022 | $24.8 | $10.4 | -58% |
| 2023 | $10.4 | $3.71 | -64% |
| 2024 | $3.71 | $3.27 | -12% |
| 2025 | $3.27 | $2.15 | -34% |
| 2026 YTD | $2.15 | $0.64 | -70% |
DARE has finished four years in a row lower, and it's down 70% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over DARE on returns for 2026, with the stronger performance.